SUBSCRIBE
SUBSCRIBE

Revolution Medicines

NEWS
Launched in 2015 with $45 Million, Bay Area Revolution Medicines Scores $25 Million
Biotech Bay
Launched in 2015 with $45 Million, Bay Area Revolution Medicines Scores $25 Million
December 20, 2016
 · 
2 min read
Load More
JOBS
IN THE PRESS
Press Releases
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
December 3, 2024
 · 
13 min read
Press Releases
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
November 28, 2024
 · 
1 min read
Press Releases
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
November 7, 2024
 · 
11 min read
Press Releases
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
October 25, 2024
 · 
7 min read
Press Releases
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
October 23, 2024
 · 
8 min read
Press Releases
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
October 21, 2024
 · 
6 min read
Business
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
October 7, 2024
 · 
6 min read
Business
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
August 7, 2024
 · 
14 min read
Business
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
July 31, 2024
 · 
1 min read
News
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
July 11, 2024
 · 
7 min read
Load More